Akoya Biosciences
NasdaqGS:AKYA
$
1,29
$
$0,00 (0,00%)
1,29
$
$0,00 (0,00%)
End-of-day quote: 07/19/2025
Akoya Biosciences Stock Value
Configure Widget
X
Create Widget
Not an affiliate? https://growth-software.de/partnerprogramm/
Widget copied to clipboard.
Akoya Biosciences Company Info
EPS Growth 5Y
40,90%
Market Cap
$0,06 B
Long-Term Debt
$0,08 B
Short Interest
0,00%
Quarterly earnings
05/15/2026 (E)
Dividend
$0,00
Dividend Yield
0,00%
Founded
2015
Industry
Country
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
There are currently no price targets available for this stock.
In the last five quarters, Akoya Biosciences’s Price Target has risen from $6,31 to $6,31 - a 0,00% increase.
Top growth stocks in the health care sector (5Y.)
What does Akoya Biosciences do?
Akoya Biosciences, Inc. (Akoya) operates as a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics.
Through its PhenoCycler and PhenoImager platforms, reagents, software, and services, the company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
The company’s spatial biology solu...
Akoya Biosciences, Inc. (Akoya) operates as a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics.
Through its PhenoCycler and PhenoImager platforms, reagents, software, and services, the company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
The company’s spatial biology solutions measure cells and proteins by providing biomarker data in its spatial context while preserving tissue integrity. Biomarkers are objective measures that capture what is happening in a cell or tissue at a given moment. Genomic and proteomic methods, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry, are providing meaningful data but require the destruction of the tissue sample for analysis. While valuable and broadly adopted, these approaches allow scientists to analyze the biomarkers and cells that comprise the tissue but do not provide the fundamental information about tissue structure, cellular interactions, and the localized measurements of key biomarkers. Furthermore, current non-destructive tissue analysis and histological methods provide some limited spatial information, but they only measure a minimal number of biomarkers at a time and require expert pathologist interpretation. The company’s platforms address these limitations by providing end-to-end solutions that enable researchers to quantitatively interrogate many biomarkers and cell types across a tissue section at single-cell resolution. The result is a detailed and computable map of the tissue sample that thoroughly captures the underlying tissue dynamics and interactions between key cell types and biomarkers, a process now referred to as spatial phenotyping.
The company offers complete end-to-end solutions for spatial phenotyping, designed to serve the unique needs of its customers in the discovery, translational and clinical markets. The PhenoCycler is an ultra-high parameter and cost-effective platform ideally suited for discovery high-plex research. The PhenoImager platforms, which include the Fusion and HT instruments, provide high throughput scalable solutions, with the automation and robustness needed for translational and clinical applications. Furthermore, the PhenoCycler and the PhenoImager Fusion can be integrated into a combined system, the PhenoCycler-Fusion, to enable spatial discovery at scale by providing significant improvements in the speed of the workflow. The company’s portfolio of products offers seamless and integrated workflow solutions for its customers, including important benefits such as flexible sample types, automated sample processing, scalability, comprehensive data analysis and software solutions and dedicated field and applications support. With these platforms, its customers are performing spatial phenotyping to further advance their understanding of diseases such as cancer, neurological and autoimmune disorders, and many other therapeutic areas.
The company licenses certain patents, know-how, and proprietary technology utilized in its PhenoCycler instrument from Stanford. To expand its offerings to the translational and clinical markets, the company acquired the Phenoptics platform (rebranded as PhenoImager) platform in 2018 from PerkinElmer, Inc. (PKI), subsequently known as Revvity, Inc. (Revvity), from whom it licenses certain patents incorporated into its PhenoImager instruments.
As of December 31, 2024, the company had 1,330 instruments installed across a broad group of customers throughout North America, Asia-Pacific (APAC), and Europe-Middle East-Africa (EMEA), reflecting an increase of 12% in its installed base over 2023.
Growth Strategy
The key elements of the company’s strategy are to leverage sales and marketing efforts to drive adoption of its solutions with new and existing customers; investments in new applications, content development and workflow improvements to drive pull through; formation of analysis software partnerships to accelerate discovery by delivering cutting-edge digital pathology and bioinformatics solutions; and investment in clinical developments to demonstrate validity.
Platforms
The company offers distinct stand-alone, as well as integrated platforms for spatial phenotyping, designed to serve the unique needs of its customers in the discovery, translational and clinical markets. The PhenoCycler is an ultra-high parameter and cost-effective platform ideally suited for discovery high-plex research. The PhenoImager platforms, which include the Fusion instrument and HT instrument, provide high throughput with the automation and robustness needed for translational and clinical applications. Furthermore, the PhenoCycler and the PhenoImager Fusion can be integrated into a combined system, the PhenoCycler-Fusion System, to enable spatial discovery at scale. Together the systems offer seamless and integrated workflow solutions for the company’s customers, including important benefits, such as flexible sample types, automated sample processing, scalability, comprehensive data analysis and software solutions and dedicated field and applications support. With these platforms, its customers are performing spatial phenotyping to further advance their understanding of diseases, such as cancer, neurological and autoimmune disorders, and many other therapeutic areas.
PhenoCycler
The company’s PhenoCycler instrument is a powerful, yet simple, compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition. It provides a comprehensive spatial biology solution, converting its customer’s standard fluorescent microscope into an automated imaging system to produce ultra-high parameter multiplex images capable of providing in situ analysis at the cellular and subcellular scales. With over 300 biobanks around the world today, most of the researchers utilizing these biobanks are using inferior products, limiting discovery and spending valuable resources. Originally developed in the lab of Dr. Garry Nolan at Stanford University, The PhenoCycler instrument uses antibodies conjugated to a proprietary library of oligonucleotides called Barcodes. This enables customizable panels of greater than 100 antibodies to be combined for a single tissue staining reaction.
PhenoImager
For a deeper understanding of disease and patient response to therapy in large scale studies, translational and clinical researchers need a robust and automated spatial biology solution. The company’s PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs) utilizing an automated and high-throughput workflow. Proprietary multispectral imaging removes the autofluorescence background and precisely measures fluorescent values for each biomarker with subcellular resolution, enabling researchers to capture the multiple interactions occurring between key biomarkers and cells. In contrast, inferior solutions on the market lack the necessary ability to precisely isolate and measure the different fluorescence channels due to color bleed. Users of its platform have confidence in the accuracy of the quantified interactions occurring in the biology of the cell. In addition, just as with PhenoCycler the company offers a simple and easy workflow to stain, image and then analyze tissue samples for the high throughput translational and clinical applications.
The Akoya PhenoImager instruments product line consists of the two PhenoImager instruments, namely the PhenoImager Fusion and PhenoImager HT. The PhenoImager Fusion is the most recent in this family of microscopes and represents the company’s high-speed whole-slide scanner ideal for everyday use of 7-color imaging and easy integration with the PhenoCycler instrument to enable ultrahigh-plex imaging solution in the translational and clinical markets.
PhenoImager Fusion: Is an automated 4-slide microscope, that enables whole-slide, multispectral imaging (MSI) at single-cell resolution at unprecedented speed. Ideal for standard throughput and high-plex applications, the PhenoImager Fusion can function as a stand-alone ultrafast imager for spatial phenotyping applications or can be integrated with the PhenoCycler instrument to form the PhenoCycler-Fusion System for spatial discovery at scale by providing significant improvements in the speed of the workflow.
PhenoCycler-Fusion 2.0: Launched in mid-2023, the PhenoCycler-Fusion 2.0 system is a package of enhancements to further improve the functionality, speed, and throughput of the discovery workflow. With the 2.0 system the slide capacity increases to 2 slides, effectively doubling the throughput of data processing and generation. Additionally, the 2.0 system introduces multi-omic capabilities by unlocking capabilities integral for future RNA workflows to facilitate side-by-side protein and RNA studies. PhenoCycler-Fusion 1.0 customers can be upgraded to 2.0 through an upgrade kit.
PhenoImager HT: The PhenoImager HT is the company’s premier and most highly cited digital pathology imager featuring rapid whole-slide multispectral scanning of up to 7 colors (6 biomarkers) with an 80-slide capacity. Because of the proprietary optical components coupled to its reagents and software, it is uniquely able to accurately detect and measure weakly expressed and overlapping biomarkers within a single tissue section. It also supports multiple applications, including Hematoxylin and Eosin (H&E), immunohistochemistry (IHC), mIF on fresh frozen or FFPE tissue section or TMA. The whole slide multispectral imaging capability creates a simpler, more robust workflow as fields of view do not need to be selected, eliminating selection bias and accelerating the time to result. The PhenoImager HT can also scan brightfield slides for downstream analysis, such as traditional DAB IHC, or scan regions of interest across a whole slide with up to 9 colors (8 biomarkers). The fully automated process provides a recorded whole slide scan, meaning no re-scans and eliminating redundant work.
PhenoImager HT 2.0: Launched in mid-2023, the PhenoImager HT 2.0 upgrade sharpens a key part of the multiplexing workflow to further ease the generation of highly accurate and quantifiable data from the HT. Specifically, the 2.0 upgrade simplifies the unmixing workflow by combining a series of steps both on and off the instrument into one step on-instrument. The new workflow significantly reduces the time from image acquisition to analysis, thereby improving speed and throughput by 5-fold. The upgrade also introduces the option of 16-bit formats in addition to the existing 8-bit images, giving customers more flexibility. HT 1.0 customers can be upgraded to 2.0 through an upgrade package.
Proprietary Reagents
PhenoCycler Reagents
PhenoCycler Antibodies: The company offers a rapidly growing menu of validated antibody content for use with PhenoCycler. Today, its menu includes over 100 unique antibodies validated for human FFPE tissue, mouse FFPE tissue, human fresh frozen tissue, and/or mouse fresh frozen tissue.
PhenoCycler Antibody Conjugation Kit: The company offers an antibody conjugation kit that allows customers to label their own proprietary antibodies of interest and modify them for use with PhenoCycler. The antibody conjugation kit can be used to add antibodies to existing content or develop entirely new content for new applications.
PhenoCycler Workflow Reagents: The company provides the full suite of additional proprietary buffers and reagents needed as part of the full PhenoCycler workflow.
PhenoCode Discovery Panels and Reagents: In 2023, the company launched its first set of ready-to-use panels focused on a particular application area within oncology. In 2024, the company launched the PhenoCode Discovery IO60 Human Protein Panel, which addresses the growing need for a comprehensive IO panel that includes an extensive set of fully validated markers. This ready-to-use solution offers researchers the ability to interrogate a wide array of immune cell types, along with key checkpoint inhibitors, components of the tumor microenvironment, and known immunotherapy targets in a single, streamlined workflow. Each panel is meticulously designed to answer key biological questions to accelerate the path from research question to discovery. The company also introduced a 24-biomarker mouse FFPE IO antibody panel designed to support preclinical research that covers essential immune cell lineage and structural markers, enabling advanced research and comparative studies between mouse and human models to deepen the understanding of cancer biology.
PhenoImager Reagents
The company offers several proprietary reagents required for the use of its platforms that are a key part of providing a seamless workflow solution to its customers. The PhenoImager Reagents portfolio includes the following: PhenoCode Signature Panels and Reagents, Opal and Tyramide Signal Amplification (TSA)-Based Detection Kits for Multiplexing, and Essentials for Staining.
PhenoCode Signature Panels and Reagents: In 2023, the company launched pre-optimized panels that consist of a five-plex base panel and one open position to add an additional biomarker of choice to the panel. Customers can choose from the company’s menu of stand-alone antibodies or barcode their own antibody of interest for use in the open position of a PhenoCode Signature panel. Panels are designed to be used across a wide variety of human FFPE tissue types, providing an additional layer of flexibility for customers. PhenoCode Signature antibodies are provided barcoded, utilizing Akoya’s proprietary universal barcoding technology to overcome workflow hurdles associated with traditional multiplexed immunofluorescence (mIF) detection in FFPE tissue. Akoya’s Opal fluorescent dyes are included in each panel kit for high sensitivity detection; panels are compatible with its PhenoImager HT and PhenoImager Fusion systems for downstream imaging.
Opal and TSA-Based Detection Kits: Opal-based detection kits are optimized for reliable spectral unmixing and offer a variety of multiplexing options to anyone performing standard immunohistochemistry (IHC). Researchers using the company’s Opal and TSA-based dyes can select antibodies at-will to develop and optimize assays for specific mIF detection needs. The company provides detection reagents for both automated and manual staining, including single dye reagent packs and pre-kitted options for multiplexing. Additionally, it offers 2 Opal-based pre-optimized panels for tissue-specific biomarker detection in human FFPE lung cancer and melanoma tissues. Both the lung cancer and melanoma six-plex panels include six ready-to-use, clinically-relevant antibodies and are compatible with automated staining followed by imaging on the PhenoImager HT or PhenoImager Fusion instruments.
Essentials for Staining: Akoya offers high quality, stand-alone reagents which are essential for Opal mIF staining, including antigen retrieval buffers, antibody blocking buffers to reduce non-specific binding and secondary antibodies.
Software Services
The company offers an ecosystem of different software options, both internal and through partnerships for its solutions to provide customers with the flexibility and ability to perform their desired work.
Analysis Software Partnerships Ecosystem
Visiopharm A/S: A digital pathology analysis provider that specializes in AI deep learning tissue analysis. It is the recommended solution for users that require on-prem software deployment and high image analysis capabilities.
Indica Labs Inc.: Indica’s HALO platform is a recognized and established brand in digital pathology. HALO is Indica’s on-prem analysis solution, and HALO AP is their cloud-based platform for streamlined pathology workflow and laboratory information management system integration. It is the recommended solution for PhenoImager clinical workflows.
Internally Developed Analysis Software
inForm Tissue: A patented automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections. The company’s software can be tailored to enable biomarker analysis in both solid tissues and TMAs from H&E, multiplexed IHC, and multiplexed immunofluorescence data. The automated, trainable algorithms permit detection, cell and tissue segmentation and identification of multiple markers within a sample. Once trained, inForm will locate and analyze user-specified regions automatically across an entire image or multiple images. Large numbers of images can be rapidly batch processed, allowing analysis that might have taken days to be done in a matter of minutes.
phenoptr & phenoptrReports: Additional software to enhance the experience with the company’s platforms. Phenoptr provides functions that consolidate and analyze output tables created by inForm software, while phenoptrReports generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
Biopharma Services
The company’s contract research services laboratory, which it calls Advanced Biopharma Solutions (ABS), enables biopharma clients to access the PhenoImager platform in a fee-for-service model to support the discovery, validation and clinical testing of predictive biomarkers to elucidate drug mechanism of action, better understand the underlying biology of disease in translational research studies and perform patient stratification and selection. The services the company offers span the entire PhenoImager workflow and include sample preparation, tissue staining, tissue imaging, image analysis pathological review and reporting. The company’s ABS lab leverages tissue autostainers, the PhenoImager HT and its proprietary software to provide automation across the entire workflow. The company’s strategic focus is partnering with top biopharma companies on clinical trials and retrospective and prospective clinical studies. The company’s ABS laboratory, based in Marlborough, Massachusetts is certified through the Clinical Laboratory Improvement Amendments (CLIA) program. This certification enables the company’s ABS lab to support later stage clinical trial studies with its biopharmaceutical partners. CLIA certification affirms that its ABS lab processes and services operate under high quality standards and provides a framework for assay development and validation that consistently meets guidelines for accuracy, precision, specificity, sensitivity, and reproducibility. This milestone is an important step towards advancing the company’s platforms toward clinical use. It further positions it as an attractive partner for biopharmaceutical companies seeking to incorporate its ground-breaking spatial biology technologies into their clinical research and oncology clinical trials.
Government Regulation
The company markets certain of its products under the FDA exemptions applicable to RUO IVD products. In addition, customers may impose contractual requirements relating to, or the company may otherwise determine that it is commercially beneficial for it to voluntarily follow, certain regulatory and industry standards, such as Quality System Regulations (QSR) and International Standards Organization (ISO) standards or other quality standards.
The company is developing companion diagnostics under the label ‘Investigational Use Only’ or IUO. Companion diagnostics are subject to a much more significant degree of potential FDA and CMS/CLIA and state laboratory regulation than its RUO product and service offerings.
Intellectual Property
The company’s key tissue labeling technology PhenoCycler originated in the laboratory of Professor Garry P.
The first patent family generally covers the CODEX 1 labeling technology in which an antibody conjugated to an oligonucleotide barcode binds to a target in a tissue sample, and extension of a primer hybridized to the barcode generates a molecular reporter that emits a detectable fluorescent signal. With respect to the CODEX 1 technology, as of December 31, 2024, the first patent family exclusively licensed from Stanford includes issued patents in the U.S., Europe, including Germany, France, United Kingdom and Sweden, China, Japan, and Australia. These patent rights relate to methods and compositions covering CODEX 1 technology. The company expects these patents to expire in 2034-2036.
The second patent family generally covers the CODEX 2 labeling technology in which an antibody conjugated to an oligonucleotide binds to a target in a tissue sample, and a second oligonucleotide conjugated to a dye hybridizes to the first oligonucleotide to generate a fluorescent molecular reporter. With respect to the CODEX 2 technology, as of December 31, 2024, the second patent family exclusively licensed from Stanford includes issued patents in the U.S., Europe including Germany, France, United Kingdom and Sweden, China, Japan, and Australia. These patent rights relate to methods and compositions covering CODEX 2 technology. The company expects these patents to expire in 2037.
The company’s key tissue imaging technology PhenoImager (formerly Phenoptics) originated at Cambridge Research and Instrumentation Inc, (Cambridge Research), a company that was later acquired by Caliper Life Sciences, Inc. (Caliper Life Sciences). Caliper Life Sciences was subsequently acquired by PKI (subsequently known as Revvity). The company purchased key patent assets covering this technology from PKI, Cambridge Research and Caliper Life Sciences, and also licensed certain supplemental patents from PKI, Cambridge Research and VisEn Medical Inc. (VisEn Medical). Some of the supplemental patents are exclusively licensed and others are non-exclusively licensed.
The PhenoImager technology is embodied in the PhenoImager HT, and in the inForm Tissue software that is supplied as part of these systems and is also available independently.
Each of the above systems is a complex combination of imaging components, sample and reagent handling components, and proprietary software. Components of the foregoing technologies that are protected by specific issued U.S. and foreign utility patents as of December 31, 2024, include, but are not limited to:
software that performs classification of cells and other components of biological tissues and is protected by four owned U.S. patents expected to expire between 2026 and 2028, and owned patents in China, India and Europe expected to expire in 2026;
systems (including sample handling components) and software that perform dilute eosin staining and imaging of tissue samples and are protected by one owned U.S. patent expected to expire in 2032, and owned patents in Canada, Japan and Europe expected to expire in 2031;
imaging components and software that perform whole slide imaging of tissue samples and registration of multispectral whole-slide images and are protected by the company’s owned U.S. patent expected to expire in 2034, and also by its owned patents in China and Europe expected to expire in 2034;
sample- and reagent-handling components, hardware control components, and software that performs pure spectrum determination for spectral unmixing of complex multispectral tissue images and are protected by one owned U.S. patent expected to expire in 2036, and also by owned patents in China and Europe expected to expire in 2035;
imaging components and software that performs RNA detection in tissue samples and are protected by an owned U.S. patent expected to expire in 2032;
software that performs real-time spectral unmixing of large multispectral images and is protected by two owned U.S. patents expected to expire between 2030 and 2031;
imaging components, hardware control components, and software that performs dynamic, spectrally-dependent adjustment of the imaging components for multispectral image acquisition and are protected by one owned U.S. patent expected to expire in 2030 and one owned European patent expected to expire in 2028;
software that identifies nuclear and non-nuclear regions in a tissue sample stained with two or more counterstains and is protected by one owned U.S. patent expected to expire in 2034;
software and hardware control components that perform illumination and measurement of samples in different combinations of illumination and emission bands to isolate contributions from multiple non-endogenous spectral contributors and background emission, which are protected by two owned U.S. patents and one owned patent in Japan, which are expected to expire in 2039;
methods and hardware components for dynamic, on-slide fluidic processing and interrogation of tissue samples, protected by one owned U.S. patent expected to expire in 2041;
compositions and methods for detecting analytes in a sample using enzyme-substrate reactions for amplification of fluorescence detection signals, protected by one reissued U.S. patent expected to expire in 2032, exclusively in-licensed from the University of Washington;
compositions and methods for detecting analytes in a sample using encoded affinity molecules and complementary encoded labeling molecules, protected by one reissued U.S. patent expected to expire in 2032, exclusively in-licensed from the University of Washington;
imaging components and software that performs spectral unmixing operations on multispectral tissue images to generate component images and are protected by six U.S. patents expected to expire between 2023 and 2026, and four patents in China and Europe expected to expire in 2023, all exclusively in-licensed from Revvity; and
software that decomposes multispectral images of tissue samples stained with an immunohistochemical stain, eosin, and a counterstain, determines a region of interest, and quantifies the immunohistochemical stain in the region of interest and is protected by one U.S. patent exclusively in-licensed from Revvity expected to expire in 2029.
The company also control patent assets (owned issued U.S. and foreign patents, owned pending patent applications, and in-licensed patent assets from third parties) covering technologies developed internally that are tied to products in development or evaluation for possible commercialization. Some of these applications are not yet open to public inspection.
As of December 31, 2024, the company’s active owned patent assets included approximately 22 issued U.S. patents, 15 pending U.S. patent applications, 56 granted patents in foreign jurisdictions (including Austria, Canada, China, the European Patent Office (the EPO), France, Germany, Ireland, India, Italy, Japan, Switzerland, and the United Kingdom), 29 pending patent applications in foreign jurisdictions and one pending Patent Cooperation Treaty application.
The subject matter covered by the company’s owned patents and patent applications includes, but is not limited to, systems and methods for sample analysis and classification, methods for spectral unmixing of spectrally dense fluorescence signals, modules and systems for performing dynamic optical correction, methods for training machine classifiers, methods and systems for RNA detection, methods for visualizing and enhancing visualization of samples, methods for visualizing compartments within cells, systems and methods for whole-slide imaging, methods for automated adjustment of imaging systems, systems and methods for multiple-image registration, systems and methods for extraction of pure spectra from sample images, methods for specialized allocation of fluorescence bands within a detection window, systems for low-volume flow cell-based sample analysis, methods for enzyme-mediated amplification of detection signals, methods for detecting receptor-coding nucleic acid segments, methods for selective labeling of targets in samples, compositions and methods for selectively targeting certain analytes, imaging methods using nanobody probes, methods for RNA sequence identification and error correction, nucleic acid-based methods for signal amplification, methods and systems for focus determination in imaging systems, and methods for catalyzed deposition of anchoring reporters in tissue samples.
Excluding any potential patent term extension, the company’s currently issued owned patents are expected to expire between 2026 and 2041.
The company also seeks to protect its brands through registration of trademark rights. As of December 31, 2024, the company owned approximately 14 registered trademarks in the United States, and 13 registered foreign trademarks. its registered trademarks include The Spatial Biology Company, Motif, Akoya Biosciences, Opal, Vectra, Proxima, PhenoCycler, PhenoCode, and PhenoImager, and its logos for Akoya Biosciences and inForm.
Licenses
Stanford University
In November 2015, the company entered into an exclusive (equity) agreement with Stanford, pursuant to which Stanford granted the company an exclusive, sublicensable (subject to certain requirements), worldwide license under certain patent rights owned by Stanford relating to oligonucleotide-based biological sample labeling to make, use and sell products and services that are covered by such patent rights (the Stanford Licensed Products) in all fields of use. The patents are related to oligonucleotide-based labeling technology, and the company refers to this technology as the CODEX 1 technology.
PKI/Revvity, Cambridge Research and VisEn Medical
In September 2018, in connection with the acquisition of the Quantitative Pathology Solutions (QPS) technology from PKI (subsequently known as Revvity), the company entered into a license and royalty agreement with PKI, Cambridge Research, and VisEn Medical, or, collectively, the Licensor, pursuant to which the Licensor granted the company an exclusive, nontransferable, sublicensable (subject to certain conditions), worldwide license within certain fields of use under certain patent rights and know-how owned by the Licensor to make, use, and sell products within such fields of use, as well as a similar, non-exclusive license under certain other patent rights. The licensed patents relate to methods and systems for analyzing biological samples, and in particular, slide-mounted tissue samples.
University of Washington
In June 2018, the company entered into an exclusive patent license agreement with the University of Washington, or the University, pursuant to which the University granted the company an exclusive, sublicensable (subject to certain conditions), worldwide license in certain fields of use under certain patent rights owned by the University relating to technology for molecular profiling of cells and tissue specimens, to make, use and sell products that are covered by such patent rights, or the Washington Licensed Products. The licensed patents are related to the detection of biomolecules, particularly proteins and nucleic acids, in biological samples.
History
Akoya Biosciences, Inc. was founded in 2015. The company was incorporated in 2015.
This stock is not included in this month's Starter.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.
Stock added to your portfolio . To add it to another portfolio, click here.
